Y0001574
美沙拉嗪
European Pharmacopoeia (EP) Reference Standard
别名:
5-氨基水杨酸, 5-AS, 5-氨基-2-羟基苯甲酸, 氨水杨酸
等级
pharmaceutical primary standard
API类
mesalazine, mesalamine
制造商/商品名称
EDQM
mp
275-280 °C (dec.) (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
Nc1ccc(O)c(c1)C(O)=O
InChI
1S/C7H7NO3/c8-4-1-2-6(9)5(3-4)7(10)11/h1-3,9H,8H2,(H,10,11)
InChI key
KBOPZPXVLCULAV-UHFFFAOYSA-N
基因信息
human ... ALOX5(240), PPARG(5468), PTGS1(5742), PTGS2(5743)
正在寻找类似产品? 访问 产品对比指南
警示用语：
Warning
危险分类
Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
靶器官
Respiratory system
储存分类代码
11 - Combustible Solids
WGK
WGK 2
闪点(°F)
No data available
闪点(°C)
No data available
Morris Gordon et al.
The Cochrane database of systematic reviews, (1)(1), CD008414-CD008414 (2011-01-21)
The use of 5-aminosalicylates (5-ASAs) in Crohn's disease (CD) is controversial. A recent Cochrane review found that 5-ASAs are not effective for the maintenance of medically-induced remission in CD, but their role in the maintenance of surgically-induced remission is unclear.
Roja Rahimi et al.
Digestive diseases and sciences, 54(4), 712-721 (2008-08-07)
5-Aminosalicylates are the standard treatment for induction and maintenance of remission in mild-to-moderate ulcerative colitis. In recent years, the 5-aminosalicylic acid-containing pro-drug balsalazide has been the focus of attention. To compare the efficacy and tolerance of balsalazide and mesalazine by
John K Marshall et al.
The Cochrane database of systematic reviews, (1)(1), CD004115-CD004115 (2010-01-22)
5-Aminosalicylates (5-ASA) are considered a first-line therapy for inducing and maintaining remission of mild to moderately active ulcerative colitis (UC). When inflammation in UC is limited to the distal colon, 5-ASA can also be administered rectally as a suppository, enema
P Desreumaux et al.
Alimentary pharmacology & therapeutics, 24 Suppl 1, 2-9 (2006-08-31)
The effectiveness of sulfasalazine depends on the splitting of the diazo bond in the molecule by the action of bacteria in the large bowel, releasing the pharmacologically active moiety, 5-aminosalicylic acid. The development of pH-dependent, delayed-release formulations of 5-aminosalicylic acid
A Lyakhovich et al.
Alimentary pharmacology & therapeutics, 31(2), 202-209 (2009-11-07)
Mesalazine (mesalamine) (5-ASA) is considered an anti-inflammatory drug for the treatment of inflammatory bowel disease. It is well tolerated by most patients and induces mucosal healing specifically in ulcerative colitis. Besides its anti-inflammatory properties, 5-ASA has been studied for cancer
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持